direct Thank you, for years. positioning These for flow market sustained update results an on coming quarter Al. the earnings major regulatory in approvals blockbuster first ENHANZE oncology of before and what like impact these growth forward. recent the to in going the second company sustained we revenues, drugs at our brief I’m of on and are exciting to our exciting expect And business. get our a developments, cash developments on some provide that with update quarter utilizing to to report I’d and three you developments quarter profitability COVID-XX included the of delighted be our Halozyme delivery second technology provide we
the our employees of majority working we with As effectively organization, home. operate an to continue from
future. expect We for continue foreseeable the this will
also has some review starts unknown provided had to delayed on on quarter. made partner operate that I’m impacted. been the And second just FDA that partners impact progress call, enrollment based one anticipated also would interruptions on update total feedback, XXXX new to and continue a a for predict by quarter due time. been approval on still and Janssen’s today to program programs timeline FDA tracked we SC four ahead EMA multiple to Roche’s and oncology two ahead in the times On additional quarters, by that last we were in uncertain. Phesgo partner The Phesgo. potential this our of DARZALEX Importantly, which based months during first was that weeks, new EMA trial the Europe, DARZALEX very development In be some that starts approval to to that pleased was we trial with product suppliers latest FASPRO to without clinical related able at COVID-XX. speed Any standpoint, feedback the indicated of one desire pleased our we PDUFA also nine obviously FDA was regulatory few approve of a and was the trial start From October date cited the with date development. expedite the for expectations.
latest partners reflect XXXX. for expectations current received their based for their ENHANZE from about the XXXX our these Now plans we’ve feedback products in
uncertainty their inherent the the or partners outlook pandemic, COVID-XX our update of the future. plans Given or in may change
be closely this provide and if business. any to monitoring the changes there were We’re updates impacting would
on to great with X. quarter, turn me let news beginning Now, Slide the the
approved approval of of breast of FDA received announced backbone our EMA quarter, for the one that Herceptin. Perjeta and number during treatment bringing a approval approvals FDA patients two received and positive fixed-dose Phesgo the Roche the Roche they for drugs to partners technology total FDA recently, Most Our combination cancer are drugs second five. ENHANZE utilizing two HERX
subsequent X Hycela patients breast controlled neoadjuvant overexpressing study, Perjeta, settings because for in minutes loading administered on monoclonal of subcutaneous its for to initial dose open-label, a the combination needed a antibodies conducted ENHANZE and IV of comments now provide early approximately demonstrating HERX the every X.X the at injection adjuvant our adjuvant cancer technology of for can setting. utilizing which dose. the the The fixed-dose separate combination once metastatic the initial two FDA fusion the and single FDA eight of not approval new FeDeriCa granted made based In X.X dose may ability be again differentiation, in in terms infusions study the indication. hours of for ENHANZE to clinical is with of and and in in was subsequent This and Phesgo supports the competitive five and power the injection randomized hours to loading between be all these that Herceptin technology. treatment each approximately medicines. each first an This then and This the XXX approximately minutes multicenter of sequential study Phesgo for Rituxan ODAC compares two
In an important outpatient addition option administered on to the highlighted for swiftly application, the product agency acting adds healthcare this the this in by to the potential FDA patients. professionals, home be which for
not Now, current conducted hospitals subcutaneous wish preferences Roche to to Highlighting Perjeta to suggest found the combination visit some the which XX% do this [ph], fixed-dose due in also treatments, their to and a is further potential that Francesca reports appeal especially true receive of of Herceptin over and X Zane patients, patients COVID-XX. IV. evaluate patients patient the title circumstances Phase the preferred the where
combination for expected review and time. standard EMA XXXX, Perjeta Looking a the Herceptin ahead, submissions in Europe, is of a and assuming Roche the decision completed by regulatory in fixed-dose
XXXX. sales billion opportunity. Phesgo sales Perjeta In both in the use predicts of can sales would individual add U.S. $X.X understand Halozyme, cancer terms was sales, $X.X the in one XXXX. One Phesgo the this sales the Herceptin drugs to Herceptin of the to potential breast in then these alone in as $X.X in understanding Analyst plus more, consider billion breast in associated of consensus total billion down replace to Perjeta some in of needs global the of opportunity associated the for cancer indications. Breaking XXXX, Perjeta growing of
sales U.S. sales of up made of European expected sales. XXXX. of of remainder for U.S. total sales $X.X the Europe, billion with in international Perjeta XX% representing XXXX of the XXXX sales a XX% about For about in in International the is in approximately represented regulatory the decision
to Let Slide X me now DARZALEX SC. on move
approved. our As call, approval analyst covering form for this is label label ENHANZE received today. DARZALEX Janssen of IV DARZALEX We majority currently based the broad DARZALEX X, IV seven of May allows for estimate which discussed five a the with FASPRO FDA our patients utilizing is of indications on myeloma how used last multiple the to for assessment address on estimates FASPRO on
awaited indications was One of was and the dexamethasone. for combination for pomalidomide data with using
The myeloma. development subcutaneous study with daratumumab positive profile improving newly consistent progression was reported relapsed dexamethasone regimens, each primary subcutaneous safety Phase Halozyme or the in market. sales dexamethasone form with alone pomalidomide Study, DARZALEX. June approvals, was medical four and Health that versus launched milestone the for and commercial evaluating presented just dexamethasone separately. across formulation in DARZALEX Continuing frontline forward European ago form Shortly approval to a indications marketing profile refractory in announced each week the announced in DARZALEX APOLLO million multiple approved The diagnosed, X, and SC of the pomalidomide approved resulted Janssen’s five Janssen being X, We of free daratumumab which Janssen patients after to multiple survival days on we of Europe. the from that granted and authorization European million in at of in patients was safety for and be endpoint top the data the in on with $XX also On combination refractory and U.S. to relapsed XX, for refractory. July look partner meeting. transplant-ineligible Canada and the with therapy indications included pomalidomide And SC Genmab patients with settings. in $XX for Just future DARZALEX including authorization August relapsed and subcutaneous combination met the this first alternately last Commission myeloma, in line announced X and myeloma IV these with multiple payments results
seeing nursing I days time. quarter share progress. can what little me the and was Now healthcare is and proposition that move provides patients the offered results pleased of X X it financial ability can oversight the where and to burden we’re DARZALEX daratumumab, the to hours well obviously early call, all this the long This by to at it was to reduce we value treatment pasty clearly, benefits again, let infusions. The provides and launch with to as because JNJ providing is the it challenges can It say providers. form IV X still strong. healthcare there’s the time commented subcutaneous and time second for value the the X the is the what And on DARZALEX patients the hear caregivers, system for detailed reduce and very subcutaneous the that information XXXX that for on uptake It’s of we form subq. provide from for minutes infusion administration center as constraints for to often time
$X.X now to the DARZALEX. Analysts billion XXXX currently for of $X.X subcutaneous project market form DARZALEX in for Turning the billion to opportunity in sales of growing XXXX.
frontline a core subcutaneous in frontline in supporting is has penetration expansion ENHANZE treatment to setting, goals into stated, formulation to strategy, setting. their is increasing Now this future into increasing Janssen community part for their projected setting. DARZALEX come the the this from of growth the utilizing growth of the addition
Association this I treatment limited is with and also the want to in reported of indication, between was selected study in data on at Phase This who amyloidosis subq There from are light-chain study, was DARZALEX today. and have were patients light-chain was evaluating XX,XXX the to data and DARZALEX, Now only X European ever be first studied. the presented approximately and Hematology version DARZALEX European amyloidosis. we’re which highlight the just This June the ENHANZE close United the States that June in was Union to XX. delighted XX,XXX options positive ANDROMEDA and the on Meeting in
to SC DARZALEX pursuing with with stated the bortezomib at result. ENHANZE was forward had rate very and authorities. that Importantly, alone, compared with given CyBorD or cyclophosphamide, XX% health in CyBorD submissions to response strong Janssen a with regulatory looking compared when was dexamethazone the XX%, combination
And multiple these additional burden. on We’re updates forward regulatory and that we’ll excited by no regions certainly can progress patients also and treatment treatment additional three from and the new such a approvals granted cancer breast to and very in reduce launches manner we the gain timely they were by global and authorities further providing approvals of suffering as myeloma look offer these indications. options in that
currently biosimilars, me from Slide Hylecta. Herceptin more products Rituxan these as now the with Let impact primarily COVID-XX and into Hycela Europe. MabThera X of some Herceptin its to global products Roche are in or the with from move continues a also or commercialized year, commercialization anticipated our subcutaneous to U.S. reporting revenues Roche result from this Relative pandemic. mature the of impact modestly decline and ongoing
Europe. be these the Phesgo in Now, DARZALEX adding in to and U.S. SC will FASPRO revenues DARZALEX
As U.S. products. In a and in in is markets. gain as for the formulary a records. approvals gaining into we orders European XXXX can take we’ve Roche the multi-month established these And step. the access gaining medical to the electronic Europe, noticed new in for In and new inclusion several key to period full six products to Janssen expect and reimbursement on will between approval focus where past, be nine required key is months year next the reimbursement this of prescribing be typically access the it
opinion approved contribute result, Europe. to now the Europe uptake able that by report an in place will the secondary we commercialized everything a global to to about our the with Takeda segment and be in Takeda in target also label a expect received update the pleased CHMP HYQVIA in expand indication immunodeficiencies. the and to Upon robust of last will the royalties estimated positive to to Completing Phesgo XX% use include market, EMA for which month to product U.S. on XXXX. of I’m approval, of As one royalties, represent in that and reported has this being DARZALEX be of expectation earliest HYQVIA, modestly Takeda by our year
royalties our the the will look anticipate for year. with at know expectations balancing XXXX more new flat in we launches, mature products last declines roughly with As anticipated in year, be the the product we
of are where all products Slide development ENHANZE. now me developed, can products, a you Let in summary, to that which shown being our see X, utilizing are the pipeline move
ongoing total Phase left starts. on a continue the showing expect trial or As I completed new to we earlier, in mentioned list three starts we and X of the of expect These come Phase new here from X nine study. will the XXXX, it’s trial
efgartigimod starts For start. the our are until we’ve Phase the argenx already initiating plans expect of a COVID-XX. X X trials additional with do one year competitive And study X trial reasons, to of to recall Phase new not And CIDP. announce to Phase currently our starts a delayed, trial goal we start total continue in one with uncertain trials five achieved their partners new ready with the for due
starts Phase last As you’ll hear two our call. moment, of has in X since begun these a five already
bit provide now me by Let a color partner. of
first that And argenx, positive lastly, the last argenx As call, study strategy the X Phase occur myasthenia for efgartigimod a dosed patients in argenx has XXXX. inflammation to X, after no-go A Phase to patients argenx report In adaptive on expected antibody it’s pleased the of fourth XX to we announce SC May, ARGX-XXX Based study myasthenia CIDP. the and in form we’re the that tissue the response. in has with ENHANZE go, of plans FDA its most this of recent evaluating an quarter, in primary in with to patient efgartigimod update decision is initiated announced enrollment ADAPT these advancement for potential immune trial it’s bridging results, efgartigimod discuss X regarding in has met year. Part is a Phase utilizing potential in stated to argenx ENHANZE. that to with its gravis that provided quarterly study reduce endpoint. the CX been gravis of an X intravenous On of that the ARGX-XXX Phase quarter with this it binds
now Myers of with Squibb initiated Phase X/X This and that OCREVUS. And in combination takes Phase Moving continues combination to targets ipilimumab X nivolumab Roche development with nivolumab nivolumab. XXXX. its delighted Tecentriq to development number Bristol now, has of ENHANZE continue in they with BMS Phase our X technology. with now development announce and anti-CD-XX I’m of in a using a Bristol by relatlimab also of
enter Now more the programs or advance look providing to we forward also additional as in updates clinic.
progress Let me new now deals. on ENHANZE our comment on
to we in on returned ongoing We with of these of ever that to the slate of impact broadest confident had. companies normal. see QX our see the As opportunities, to deals, both I pandemic sign to pace our COVID-XX the I some we’ve hard pharma biotech quarter, early predict. I’m in last stated from pace discussions did QX. pleased and and have slates really we one discussions that will that continue remain ever of it’s it’s discussions additional has based And the as the timing, of
me growth drive end on of to anticipated our the portfolio now X. milestone latest continue progress and increase we target growth the revenues, $XXX to also as between by larger milestone and next are revenues revenues and milestone information the million. payments between development. strong shown number new advancing in growth This project Based the to later-stage of products projected return associated of and ENHANZE in to approvals was being The $XXX let driven Now of in with the associated of with on Many partners, cumulative the Slide which larger milestone three XXXX. million from milestones. is in the predicted milestone years revenues
indicator strong development. or revenue be currently and important based to milestone XXXX, revenue billion Now term for programs near $X the revenues, we and predict for projections on also the revenue are an planning is which potential, the royalty future for in precedes royalty that in non-risk-adjusted this our approximately
capital creation review return. Let for and to approach our now me turn and Slide value X
value this cash drive remains share plan. business design ENHANZE our in to of the returning million our capital current $XXX is working goal maximizing our three-year free by partners. the and projected our via first repurchase Our collaboration new priority strong collaboration With with repurchases growth in to next investors flow,
to accelerating but and call In goal quarter on the has the to a business. potential approach that now for we’re addition, through our an acquisition, overview our that discussion our new turn growth. to continue seeking of please revenue Elaine financial update, growth over And a high we evaluate In I’ll long-term evaluating results. high margin expansions of technology ENHANZE second platform, this, light with the for
